Jellagen supplies medical‑grade Collagen Type 0 extracted from jellyfish, using a proprietary process that preserves the native triple‑helix structure. The non‑mammalian, ethically sourced collagen is offered in versatile formats such as micronized powder, enabling researchers and manufacturers to develop wound‑care dressings, bone and cartilage repair scaffolds, and implantable devices with reduced safety and regulatory concerns.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Regenerative medicine and tissue engineering rely heavily on mammalian collagen, which poses risks of disease transmission, ethical concerns, and batch variability, limiting the safety and scalability of medical-grade biomaterials.
Solution
Jellagen produces medical‑grade Collagen Type 0 extracted from jellyfish using a proprietary process that preserves the native triple‑helix structure. This non‑mammalian source eliminates zoonotic and religious safety issues while providing a universally compatible biomaterial for both in‑vitro and in‑vivo applications. The collagen is supplied in multiple formulations, including micronized powder for wound dressings, enabling direct integration into advanced wound care, bone and cartilage repair, and implantable device development. By offering a sustainably sourced, ethically derived, and biocompatible collagen platform, Jellagen supports researchers and manufacturers in creating next‑generation regenerative therapies with reduced regulatory and supply‑chain barriers.
Target Audience
Primary customers are biomedical researchers, tissue‑engineering companies, and medical‑device manufacturers developing regenerative therapies, wound‑care products, and implantable devices.
Features
- Proprietary extraction method that retains the intact triple‑helix structure of collagen
- Non‑mammalian jellyfish source, avoiding disease transmission and religious constraints
- Versatile formulations (e.g., micronized powder) suitable for wound dressings, scaffolds, and bio‑inks
- Demonstrated biocompatibility and anti‑inflammatory properties in both in‑vitro and in‑vivo studies
- ISO 13485:2016‑certified manufacturing facility with clean‑room capabilities for medical‑grade production
- Ethically and environmentally sourced raw material with a sustainable supply chain